Reuters logo
BRIEF-Tetraphase Pharmaceuticals, Patheon UK enters into master manufacturing services agreement
2017年6月20日 / 晚上8点46分 / 3 个月前

BRIEF-Tetraphase Pharmaceuticals, Patheon UK enters into master manufacturing services agreement

June 20 (Reuters) - Tetraphase Pharmaceuticals Inc-

* Tetraphase Pharmaceuticals - on June 14, 2017, tetraphase pharmaceuticals, Patheon UK Ltd and certain of its affiliates entered into master manufacturing services agreement

* Tetraphase Pharmaceuticals - under master agreement co is responsible for supplying active pharmaceutical ingredient for eravacycline to patheon

* Tetraphase Pharmaceuticals - expects to enter into 2 related product agreements to govern terms and conditions of patheon’s manufacture of commercial supplies of eravacycline

* Tetraphase Pharmaceuticals - master agreement initial term ends Dec 31, 2022, and will automatically renew after that for successive terms of 2 yrs each Source text: (bit.ly/2tq3zmZ) Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below